|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
 |
 |
|
|
a Ibis Biosciences, Inc., a Subsidiary of Isis Pharmaceuticals, Carlsbad, California, USA
Key Words: PCR • RT-PCR • ESI-MS • mass spectrometry • infectious disease surveillance • viral diseases • broad detection • emerging infections
Address for correspondence: Rangarajan Sampath, Ibis Biosciences, Inc., a subsidiary of Isis Pharmaceuticals, 1891 Rutherford Rd., Carlsbad, CA 92008, USA. Voice: 760-603-2652; fax: 760-603-4653. rsampath{at}ibisbio.com
Newly emergent infectious diseases are a global public health problem. The population dense regions of Southeast Asia are the epicenter of many emerging diseases, as evidenced by the outbreak of Nipah, SARS, avian influenza (H5N1), Dengue, and enterovirus 71 in this region in the past decade. Rapid identification, epidemiologic surveillance, and mitigation of transmission are major challenges in ensuring public health safety. Here we describe a powerful new approach for infectious disease surveillance that is based on polymerase chain reaction (PCR) to amplify nucleic acid targets from large groupings of organisms, electrospray ionization mass spectrometry (ESI-MS) for accurate mass measurements of the PCR products, and base composition signature analysis to identify organisms in a sample. This approach is capable of automated analysis of more than 1,500 PCR reactions a day. It is applicable to the surveillance of bacterial, viral, fungal, or protozoal pathogens and will facilitate rapid characterization of known and emerging pathogens.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||
 |
 |
